文献速递造血干细胞移植与细胞治疗

用Fas配体蛋白工程化供体淋巴细胞可有效预防急性移植物抗宿主病

Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease.
PubMed 文献 · Blood Adv · 2023-01-01

研究将链霉亲和素融合的Fas配体蛋白(SA-FasL)瞬时展示在生物素化淋巴细胞表面,利用FasL介导的再刺激诱导细胞死亡(RICD)清除宿主反应性T效应细胞。在致死照射半相合小鼠中,SA-FasL工程化脾细胞与骨髓共移植使>70%受体免于aGVHD,而所有对照均发生aGVHD;该保护与Treg/Teff比值升高及促炎细胞因子转录本减少相关,去除Treg则保护消失。

要点

  • SA-FasL工程化小鼠和人T细胞在体外和体内经同种抗原激活后发生凋亡。
  • 致死照射半相合小鼠共移植SA-FasL脾细胞后>70%预防aGVHD,对照全部发生aGVHD。
  • 保护伴随CD4+CD25+FoxP3+ Treg与Teff比值升高、淋巴器官和靶组织促炎细胞因子转录本显著减少;去除Treg则保护消失。

核心结论

  • 将SA-FasL蛋白直接展示在供体细胞上是清除宿主体内同种反应性Teff的有效手段,为预防aGVHD提供了具有显著转化潜力的实用方法。

研究设计与样本

  • 研究采用SA-FasL蛋白与链霉亲和素融合,利用生物素与链霉亲和素的高亲和力相互作用,将SA-FasL瞬时展示在生物素化淋巴细胞表面。
  • 在体外和体内评估SA-FasL工程化小鼠和人T细胞对同种抗原激活后的凋亡反应。
  • 在致死照射半相合小鼠中,将SA-FasL工程化脾细胞与骨髓细胞共移植,观察aGVHD预防效果。
  • 在异种aGVHD模型中,将SA-FasL工程化人外周血单个核细胞(PBMCs)移植入NSG小鼠。

主要发现

  • SA-FasL工程化小鼠和人T细胞在体外和体内经同种抗原激活后发生凋亡。
  • 在致死照射半相合小鼠中,共移植SA-FasL脾细胞后>70%受体免于aGVHD,而所有接受未工程化脾细胞移植的对照均发生aGVHD。
  • aGVHD预防与CD4+CD25+FoxP3+ Treg与Teff比值升高及淋巴器官和靶组织中促炎细胞因子转录本显著减少相关。
  • 从供体移植物中去除Treg可消除SA-FasL赋予的保护。
  • 在SA-FasL工程化人PBMCs移植入NSG小鼠的异种aGVHD模型中,该方法同样有效。

关键数值与推荐

  • SA-FasL工程化脾细胞使>70%致死照射半相合小鼠受体预防aGVHD,对照全部发生aGVHD。

临床怎么用

  • 作者认为,将SA-FasL蛋白直接展示在供体细胞上是清除宿主体内同种反应性Teff的有效手段,为预防aGVHD提供了具有显著转化潜力的实用方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alloreactive T-effector cells (Teffs) are the major culprit of acute graft-versus-host disease (aGVHD) associated with hematopoietic stem cell transplantation. Ex vivo nonspecific depletion of T cells from the donor graft impedes stem cell engraftment and posttransplant immune reconstitution. Teffs upregulate Fas after activation and undergo Fas ligand (FasL)-mediated restimulation-induced cell death (RICD), an important mechanism of immune homeostasis. We targeted RICD as a means to eliminate host-reactive Teffs in vivo for the prevention of aGVHD. A novel form of FasL protein chimeric with streptavidin (SA-FasL) was transiently displayed on the surface of biotinylated lymphocytes, taking advantage of the high-affinity interaction between biotin and streptavidin. SA-FasL-engineered mouse and human T cells underwent apoptosis after activation in response to alloantigens in vitro and in vivo. SA-FasL on splenocytes was effective in preventing aGVHD in >70% of lethally irradiated haploidentical mouse recipients after cotransplantation with bone marrow cells, whereas all controls that underwent transplantation with nonengineered splenocytes developed aGVHD. Prevention of aGVHD was associated with an increased ratio of CD4+CD25+FoxP3+ T regulatory (Tregs) to Teffs and significantly reduced transcripts for proinflammatory cytokines in the lymphoid organs and target tissues. Depletion of Tregs from the donor graft abrogated the protection conferred by SA-FasL. This approach was also effective in a xenogeneic aGVHD setting where SA-FasL-engineered human PBMCs were transplanted into NSG mice. Direct display of SA-FasL protein on donor cells as an effective means of eliminating alloreactive Teffs in the host represents a practical approach with significant translation potential for the prevention of aGVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shrestha P, Turan A, Batra L, et al. Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease. Blood Adv. 2023. PMID: 36780582. doi:10.1182/bloodadvances.2022008495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。